ADMP - Adamis Pharmaceuticals jumps 36% on DMK Pharmaceuticals merger plan

• Specialty biopharmaceutical company focused on developing and commercializing products in various therapeutic areas, including opioid overdose, allergy, respiratory and inflammatory disease Adamis Pharmaceuticals ( ADMP ) and DMK Pharmaceuticals plan a merger .
• DMK Pharmaceuticals is a clinical-stage biotechnology company at the forefront of endorphin-inspired drug design focused on developing novel treatments for opioid use disorder and other neuro-based diseases,
• Adamis will acquire DMK, including its library of ~750 small molecule neuropeptide analogues and on-going government funding for its development programs.
• At the close of the merger, Eboo Versi, the current CEO of DMK, will assume the role of CEO and chairman of the combined company.
• A reverse stock split of Adamis stock will likely be consummated, pursuant to which a number of outstanding shares of ADMP stock will be converted into one share, subject to shareholders approval.
• ADMP price jumps 36%.

For further details see: